▶ 調査レポート

男性性腺機能低下症治療の世界市場

• 英文タイトル:Global Market Study on Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism during 2017 - 2026

Persistence Market Researchが調査・発行した産業分析レポートです。男性性腺機能低下症治療の世界市場 / Global Market Study on Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism during 2017 - 2026 / B-PMR-MA14資料のイメージです。• レポートコード:B-PMR-MA14
• 出版社/出版日:Persistence Market Research / 2018年2月28日
• レポート形態:英文、PDF、170ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Individual(1名、印刷不可)¥519,400 (USD4,900)▷ お問い合わせ
  Multi User(5名)¥805,600 (USD7,600)▷ お問い合わせ
  Corporate User¥1,123,600 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートでは、男性性腺機能低下症治療の世界市場について調査・分析し、関連企業情報、産業分析、男性性腺機能低下症治療の世界市場規模、市場動向、セグメント別市場分析、地域別市場規模(欧州、アメリカ、アジアなど)、市場予測データを含め、以下の構成でお届けいたします。

Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can vary in terms of severity among individuals. Partial or complete infertility are among major end-results entailing male hypogonadism, which in turn have created the need for effective treatment. Persistence Market Research has published a new comprehensive research report titled, “Male Hypogonadism Market: Global Industry Analysis (2012-2016) and Forecast (2017-2026)”. The report covers present market scenario as well as imparts future growth prospects of the male hypogonadism market for the period between 2017 and 2026. The report also engulfs key drivers, hindrances, opportunities and trends that are affecting expansion of the global male hypogonadism market. The report offers an overall picture of the global male hypogonadism market, in order to help businesses seeking opportunities for making investments in the market.
Structure of the Report

The report provides an exhaustive synopsis of the global male hypogonadism market, engulfing an executive summary that elucidates the core trends influencing the market expansion. This chapter also sheds light on impacts that the dynamics are likely to pose on growth of the market in the long run. The report also imparts figures appertaining to CAGRs from a historical and forecast point of view. An overview of the global male hypogonadism market follows the executive summary, and issues a clear picture of the market’s scope to the report readers. The overview includes a concise market introduction succeeded by a formal definition of “male hypogonadism”. Chapters subsequent to the overview elaborates several dynamics including driving factors, limitations and prospects being observed in the market through the forecast period. Meanwhile these chapter also inundate detailed insights related to the bottom line of enterprises, global economy and fiscal stimulus.Competition Landscape

This analytical research report on the global male hypogonadism market is a complete package, which includes intelligence on key participants underpinning the market expansion. In the last chapter of the report, which elucidates the competitive scenario of the market, strategies implemented by the market players, along with their product overview, company overview, key financials, key developments and SWOT analysis has been rendered exhaustively. In addition, region-wide spread of these market players, their future expansion plans, market shares, revenues, and mergers & acquisition activities between them have been described in detail in this concluding chapter of the report. An intensity map has been employed in the report to profile the market players situated across geographies.

Research Methodology

Credibility of the researched statistics and data is backed by the unique research methodology employed by the analysts at PMR, which ensures higher accuracy. PMR’s research report on the global male hypogonadism market can assist its readers in gaining detailed insights on many different aspects governing the market around key regional segments included in the report. The report readers can further slate key strategies for tapping into vital revenue pockets and gaining benefits over the intensifying competition in the market. Information presented in the report has been scrutinized and monitored thoroughly by PMR’s industry experts. Figures and numbers offered in the report have also been validated by the analysts in order to facilitate strategic decision making for the report readers.

レポート目次

1. Global Economic Outlook

2. Global Male Hypogonadism Market – Executive Summary
2.1. Opportunity Analysis – Male Hypogonadism Market

3. Global Male Hypogonadism Market Overview
3.1. Introduction
3.1.1. Global Male Hypogonadism Market Taxonomy
3.1.2. Global Male Hypogonadism Market Definition
3.2. Global Male Hypogonadism Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Male Hypogonadism Market Y-o-Y Growth
3.3. Global Male Hypogonadism Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. Pricing Analysis
3.7. PESTL Analysis
3.8. Product Life Cycle Analysis
3.9. Epidemiology
3.10. List of Distributors
3.11. Key Participants Market Presence (Intensity Map) By Region

4. Global Male Hypogonadism Market Analysis and Forecast 2012-2026
4.1. Global Male Hypogonadism Market Size and Forecast By Therapy , 2012-2026
4.1.1. Testosterone Replacement Therapy Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Gonadotropin Replacement Therapy Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.2. Global Male Hypogonadism Market Size and Forecast By Drug Type, 2012-2026
4.2.1. Topical Gels Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Injectables Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.2.3. Transdermal Patches Market Size and Forecast, 2012-2026
4.2.3.1. Revenue (US$ Mn) Comparison, By Region
4.2.3.2. Market Share Comparison, By Region
4.2.3.3. Y-o-Y growth Comparison, By Region
4.2.4. Others Market Size and Forecast, 2012-2026
4.2.4.1. Revenue (US$ Mn) Comparison, By Region
4.2.4.2. Market Share Comparison, By Region
4.2.4.3. Y-o-Y growth Comparison, By Region
4.3. Global Male Hypogonadism Market Size and Forecast By Disease Type, 2012-2026
4.3.1. Klinefelter’s Syndrome Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Pituitary Adenomas Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Kallmann Syndrome Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.3.4. Other Types Market Size and Forecast, 2012-2026
4.3.4.1. Revenue (US$ Mn) Comparison, By Region
4.3.4.2. Market Share Comparison, By Region
4.3.4.3. Y-o-Y growth Comparison, By Region

5. North America Male Hypogonadism Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Therapy
5.6. Revenue (US$ Mn) Comparison, By Drug Type
5.7. Revenue (US$ Mn) Comparison, By Disease Type

6. Latin America Male Hypogonadism Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Therapy
6.6. Revenue (US$ Mn) Comparison, By Drug Type
6.7. Revenue (US$ Mn) Comparison, By Disease Type

7. Europe Male Hypogonadism Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Therapy
7.6. Revenue (US$ Mn) Comparison, By Drug Type
7.7. Revenue (US$ Mn) Comparison, By Disease Type

8. Japan Male Hypogonadism Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Revenue (US$ Mn), 2012-2026
8.4.1. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Therapy
8.6. Revenue (US$ Mn) Comparison, By Drug Type
8.7. Revenue (US$ Mn) Comparison, By Disease Type

9. APEJ Male Hypogonadism Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Therapy
9.6. Revenue (US$ Mn) Comparison, By Drug Type
9.7. Revenue (US$ Mn) Comparison, By Disease Type

10. MEA Male Hypogonadism Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Israel Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Therapy
10.6. Revenue (US$ Mn) Comparison, By Drug Type
10.7. Revenue (US$ Mn) Comparison, By Disease Type

11. Global Male Hypogonadism Market Company Share, Competition Landscape and Company Profiles
11.1. Company Share Analysis
11.2. Competition Landscape
11.3. Company Profiles
11.3.1. Endo International Plc
11.3.2. Eli Lilly and Company Ltd.
11.3.3. AbbVie, Inc.
11.3.4. Pfizer, Inc.
11.3.5. Merck KGaA
11.3.6. Allergan Plc
11.3.7. Sun Pharmaceutical Industries Limited
11.3.8. Ferring B.V.
11.4. Key takeaways – Male Hypogonadism Market

12. Research Methodology

13. Secondary and Primary Sources

14. Assumptions and Acronyms

15. Disclaimer

List of Tables

TABLE 1 Global Male Hypogonadism Market Value (US$ Mn), 2012-2017
TABLE 2 Global Male Hypogonadism Market Value (US$ Mn), 2018-2026
TABLE 3 Global Male Hypogonadism Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Testosterone Replacement Therapy Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Testosterone Replacement Therapy Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Testosterone Replacement Therapy Segment Market Share, By Region 2012-2017
TABLE 7 Global Testosterone Replacement Therapy Segment Market Share, By Region 2018-2026
TABLE 8 Global Testosterone Replacement Therapy Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Gonadotropin Replacement Therapy Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Gonadotropin Replacement Therapy Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Gonadotropin Replacement Therapy Segment Market Share, By Region 2012-2017
TABLE 12 Global Gonadotropin Replacement Therapy Segment Market Share, By Region 2018-2026
TABLE 13 Global Gonadotropin Replacement Therapy Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Topical Gels Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Topical Gels Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Topical Gels Segment Market Share, By Region 2012-2017
TABLE 17 Global Topical Gels Segment Market Share, By Region 2018-2026
TABLE 18 Global Topical Gels Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Injectables Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Injectables Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Injectables Segment Market Share, By Region 2012-2017
TABLE 22 Global Injectables Segment Market Share, By Region 2018-2026
TABLE 23 Global Injectables Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Transdermal Patches Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Transdermal Patches Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Transdermal Patches Segment Market Share, By Region 2012-2017
TABLE 27 Global Transdermal Patches Segment Market Share, By Region 2018-2026
TABLE 28 Global Transdermal Patches Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Others Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Others Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Others Segment Market Share, By Region 2012-2017
TABLE 32 Global Others Segment Market Share, By Region 2018-2026
TABLE 33 Global Others Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Klinefelter's Syndrome Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Klinefelter's Syndrome Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Klinefelter's Syndrome Segment Market Share, By Region 2012-2017
TABLE 37 Global Klinefelter's Syndrome Segment Market Share, By Region 2018-2026
TABLE 38 Global Klinefelter's Syndrome Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Pituitary Adenomas Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Pituitary Adenomas Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Pituitary Adenomas Segment Market Share, By Region 2012-2017
TABLE 42 Global Pituitary Adenomas Segment Market Share, By Region 2018-2026
TABLE 43 Global Pituitary Adenomas Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Kallmann Syndrome Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Kallmann Syndrome Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Kallmann Syndrome Segment Market Share, By Region 2012-2017
TABLE 47 Global Kallmann Syndrome Segment Market Share, By Region 2018-2026
TABLE 48 Global Kallmann Syndrome Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global Other Types Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global Other Types Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global Other Types Segment Market Share, By Region 2012-2017
TABLE 52 Global Other Types Segment Market Share, By Region 2018-2026
TABLE 53 Global Other Types Segment Y-o-Y, By Region 2017-2026
TABLE 54 North America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 55 North America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 56 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 57 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 58 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 59 North America Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 60 North America Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 61 North America Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 62 North America Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 63 North America Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 64 North America Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 65 North America Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 66 North America Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026
TABLE 67 Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 68 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 69 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 70 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 71 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 72 Latin America Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 73 Latin America Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 74 Latin America Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 75 Latin America Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 76 Latin America Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 77 Latin America Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 78 Latin America Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 79 Latin America Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026
TABLE 80 Europe Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 81 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 82 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 83 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 84 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 85 Europe Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 86 Europe Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 87 Europe Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 88 Europe Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 89 Europe Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 90 Europe Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 91 Europe Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 92 Europe Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026
TABLE 93 Japan Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 94 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 95 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 96 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 97 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 98 Japan Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 99 Japan Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 100 Japan Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 101 Japan Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 102 Japan Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 103 Japan Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 104 Japan Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 105 Japan Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026
TABLE 106 APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 107 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 108 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 109 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 110 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 111 APEJ Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 112 APEJ Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 113 APEJ Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 114 APEJ Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 115 APEJ Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 116 APEJ Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 117 APEJ Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 118 APEJ Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026
TABLE 119 MEA Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 120 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 121 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 122 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 123 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 124 MEA Male Hypogonadism Market Value (US$ Mn), By Country 2012-2017
TABLE 125 MEA Male Hypogonadism Market Value (US$ Mn), By Country 2018-2026
TABLE 126 MEA Male Hypogonadism Market Value (US$ Mn), By Therapy 2012-2017
TABLE 127 MEA Male Hypogonadism Market Value (US$ Mn), By Therapy 2018-2026
TABLE 128 MEA Male Hypogonadism Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 129 MEA Male Hypogonadism Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 130 MEA Male Hypogonadism Market Value (US$ Mn), By Disease Type 2012-2017
TABLE 131 MEA Male Hypogonadism Market Value (US$ Mn), By Disease Type 2018-2026